EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
作者： Stefanie Derer , Stefan Lohse , Thomas Valerius
DOI: 10.4161/ONCI.24052
关键词: Egfr expression 、 Monoclonal antibody 、 Affect (psychology) 、 Phosphorylation 、 Epidermal growth factor receptor 、 Pharmacology 、 Mode of action 、 Medicine 、 Antibody 、 Immunology 、 Immunology and Allergy 、 Oncology
摘要: Epidermal growth factor receptor (EGFR) expression levels appear to modulate the efficacy of EGFR-targeting monoclonal antibodies. More specifically, we observed that high EGFR densities negatively affect effects EGFR-specific antibodies on phosphorylation yet exacerbate Fc-mediated tumor-cell killing. These results suggest predominant mode action depend levels.
sci-hub.se 参考文章(12)
Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J. Lammerts van Bueren, Jan G.J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius, Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression Neoplasia. ,vol. 14, pp. 190- 205 ,(2012) , 10.1593/NEO.111636
Klaus Koefoed, Lucilla Steinaa, Josefine Nielsen Søderberg, Ida Kjær, Helle Jane Jacobsen, Per-Johan Meijer, John Sørensen Haurum, Allan Jensen, Michael Kragh, Peter Sejer Andersen, Mikkel Wandahl Pedersen, Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor mAbs. ,vol. 3, pp. 584- 595 ,(2011) , 10.4161/MABS.3.6.17955
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy OncoImmunology. ,vol. 3, ,(2014) , 10.4161/ONCI.27048
Matthias Peipp, Michael Dechant, Thomas Valerius, Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. mAbs. ,vol. 1, pp. 590- 599 ,(2009) , 10.4161/MABS.1.6.10051
Katja Klausz, Sven Berger, Jeroen J. Lammerts van Bueren, Stefanie Derer, Stefan Lohse, Michael Dechant, Jan G. J. van de Winkel, Matthias Peipp, Paul W. H. I. Parren, Thomas Valerius, Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII) Cancer Science. ,vol. 102, pp. 1761- 1768 ,(2011) , 10.1111/J.1349-7006.2011.02019.X
Ralf Lutterbuese, Tobias Raum, Roman Kischel, Patrick Hoffmann, Susanne Mangold, Benno Rattel, Matthias Friedrich, Oliver Thomas, Grit Lorenczewski, Doris Rau, Evelyne Schaller, Ines Herrmann, Andreas Wolf, Thomas Urbig, Patrick A. Baeuerle, Peter Kufer, T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 12605- 12610 ,(2010) , 10.1073/PNAS.1000976107
Lisa Licitra, Stephan Störkel, Keith M. Kerr, Eric Van Cutsem, Robert Pirker, Fred R. Hirsch, Jan B. Vermorken, Anja von Heydebreck, Regina Esser, Ilhan Celik, Fortunato Ciardiello, Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies European Journal of Cancer. ,vol. 49, pp. 1161- 1168 ,(2013) , 10.1016/J.EJCA.2012.11.018
Joshua M. Donaldson, Csaba Kari, Ruben C. Fragoso, Ulrich Rodeck, John C. Williams, Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies Cancer Biology & Therapy. ,vol. 8, pp. 2147- 2152 ,(2012) , 10.4161/CBT.8.22.9765
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, Andres Cervantes, Ben Markman, Jesus Corral, Jean-Charles Soria, Yann Bergé, Desamparados Roda, Fiona Russell-Yarde, Simon Hollingsworth, José Baselga, Pablo Umana, Luigi Manenti, Josep Tabernero, None, Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology. ,vol. 29, pp. 3783- 3790 ,(2011) , 10.1200/JCO.2011.34.8888
Lorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean-Pierre Abastado, Patrizia Agostinis, Ron N. Apte, Fernando Aranda, Maha Ayyoub, Philipp Beckhove, Jean-Yves Blay, Laura Bracci, Anne Caignard, Chiara Castelli, Federica Cavallo, Estaban Celis, Vincenzo Cerundolo, Aled Clayton, Mario P. Colombo, Lisa Coussens, Madhav V. Dhodapkar, Alexander M. Eggermont, Douglas T. Fearon, Wolf H. Fridman, Jitka Fučíková, Dmitry I. Gabrilovich, Jérôme Galon, Abhishek Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Pawel Kalinski, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, Jean-Pierre Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, Anna Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer Rizvi, Catherine Sautès-Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva-Santos, Mark J. Smyth, Daniel E. Speiser, Radek Spisek, Pramod K. Srivastava, James E. Talmadge, Eric Tartour, Sjoerd H. Van Der Burg, Benoît J. Van Den Eynde, Richard Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou, Guido Kroemer, Classification of current anticancer immunotherapies Oncotarget. ,vol. 5, pp. 12472- 12508 ,(2014) , 10.18632/ONCOTARGET.2998